Synklino
Synklino is a clinical stage biotechnology company pioneering transformative therapies for solid organ transplantation. Our first-in-class drug candidate, SYN002, is a therapeutic fusion protein designed to eliminate both active and latent CMV infection in donated organs through ex vivo organ perfusion, offering a proactive and life-changing therapy for immunocompromised transplant recipients. With regulatory clearance and funding in place, we are on track to deliver clinical data from kidney transplant recipients through 2026.
7-day free trial · no credit card
Verified contacts
8
available on Kipplo
LinkedIn employees
13
1 to 10 range
Open roles
—
no listings
Distinct roles
6
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 8 verified contacts at Synklino
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
8 contacts with verified email or phone · masked until revealed.
Showing 1 of 8 verified contacts
Top roles at Synklino
6 distinct titles indexed · top 6 shown.
- 1board member
- 1board observer
- 1ceo & co-founder
- 1chief operating officer
- 1head of discovery
- 1project director
Sign up to unlock all 8 contacts at Synklino
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 8 verified contacts at Synklino
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.